Stay updated on Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.

Latest updates to the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedAn update to the page revision from v3.6.2 to v3.6.3 was applied, signaling a new version of the page. This change records a version bump rather than a modification to the trial content.SummaryDifference0.1%

- Check25 days agoChange DetectedA new Revision: v3.6.2 tag appears on the page, replacing the previous v3.6.0 tag. This indicates a platform or content update rather than a substantive change to the study information.SummaryDifference0.1%

- Check39 days agoChange DetectedThe page adds new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and shows recruitment status as No longer looking for participants. The Intervention/Treatment label is standardized (replacing Intervention / Treatment) and the revision tag updated from v3.5.5 to v3.6.0.SummaryDifference0.4%

- Check46 days agoChange DetectedThe page's revision history now includes a new entry 'Revision: v3.5.5' and removes the previous 'Revision: v3.5.4' entry. This update represents a minor administrative change to the page metadata rather than user-facing content or functionality.SummaryDifference0.1%

- Check68 days agoChange DetectedThis page now shows Revision: v3.5.4, replacing the previous v3.5.3 revision. This indicates a small update to the page record without altering the study details or required actions for participants.SummaryDifference0.1%

- Check90 days agoChange DetectedThis change updates the ClinicalTrials.gov page revision version from v3.5.2 to v3.5.3, reflecting a site/software metadata update rather than a change to the underlying study record content.SummaryDifference0.1%

Stay in the know with updates to Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.